Market revenue in 2023 | USD 73.9 million |
Market revenue in 2030 | USD 206.9 million |
Growth rate | 15.8% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 55.48% in 2023. Horizon Databook has segmented the Sweden structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
The structural heart devices market in Sweden is undergoing remarkable expansion, fueled by several key factors, including the escalating prevalence of cardiovascular ailments and the country’s commitment to embracing cutting-edge healthcare technologies.
Positioned as a pivotal player within the European landscape, Sweden is actively advancing its healthcare infrastructure to cater to evolving patient needs. Central to this growth is the mounting incidence of SHD, necessitating sophisticated interventions like TAVI.
TAVI stands as a cornerstone within structural heart devices, offering minimally invasive solutions for rectifying heart defects, mitigating stroke risks, and addressing congenital heart anomalies. Employing a transcatheter approach, TAVI obviates the requirement for conventional open-heart surgery, thereby facilitating swifter recuperation periods.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden structural heart devices market , including forecasts for subscribers. This country databook contains high-level insights into Sweden structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account